RT Journal Article
SR Electronic
T1 Potential health and economic impact of paediatric vaccination using next generation influenza vaccines in Kenya: a modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.26.22279262
DO 10.1101/2022.08.26.22279262
A1 Waterlow, Naomi R
A1 Radhakrishnan, Sreejith
A1 Dawa, Jeanette
A1 van Leeuwen, Edwin
A1 Lambach, Philipp
A1 Bresee, Joseph
A1 Mazur, Marie
A1 Eggo, Rosalind M
A1 Jit, Mark
YR 2022
UL http://medrxiv.org/content/early/2022/08/26/2022.08.26.22279262.abstract
AB Background Influenza is a major year-round cause of respiratory illness in Kenya, particularly in children under 5. Current influenza vaccines result in short-term, strain-specific immunity and were found in a previous study not to be cost-effective in Kenya. However, next generation vaccines are in development that may have a greater impact and cost-effectiveness profile.Methods We expanded a model previously used to evaluate cost-effectiveness of seasonal influenza vaccines in Kenya to include next generation vaccines by allowing for enhanced vaccine characteristics and multi-annual immunity. We specifically examined vaccinating children under 5 years of age with improved vaccines, evaluating vaccines with combinations of increased vaccine effectiveness, cross protection between strains (breadth) and duration of immunity. We evaluated cost-effectiveness using incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefits (INMBs) for a range of values for the willingness-to-pay (WTP) per DALY averted. Finally, we estimated threshold per-dose vaccine prices at which vaccination becomes cost-effective.Results Next generation vaccines can be cost-effective, dependent on the vaccine characteristics and assumed WTP thresholds. Universal vaccines (assumed to provide long-term and broad immunity) are most cost-effective in Kenya across three of four WTP thresholds evaluated, with the lowest median value of ICER per DALY averted ($263, 95% Credible Interval (CrI): $-1698, $1061) and the highest median INMBs. At a WTP of $623, universal vaccines are cost-effective at or below a median price of $5.16 per dose (95% CrI: $0.94, $18.57). We also show that the assumed mechanism underlying infection-derived immunity strongly impacts vaccine outcomes.Conclusion This evaluation provides evidence for country-level decision makers about future next generation vaccine introduction, as well as global research funders about the potential market for these vaccines. Next generation vaccines may offer a cost-effective intervention to reduce influenza burden in low-income countries with year-round seasonality like Kenya.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome Trust, Centers for Disease Control and Prevention and Taskforce for Global Health via the grant Modeling cost-effectiveness of improved seasonal influenza vaccines in two exemplar countries. JB was funded by PIVI and CDC. EvL and RME were also supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health Economics, a partnership between UK HSA, Imperial College London, and LSHTM (grant number NIHR200908) and EvL was also supported by the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study only used publically availble data that were orginially located in the Supplement of Dawa et al. (2020). https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-7#Sec18I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used is available in the Supplement of Dawa et al. (2020). https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-7#Sec18 CrICredible IntervalDALYdisability-adjusted life yearsEExposedGDPgross domestic productHAhaemagglutininIinfectiousICERincremental cost-effectiveness ratioINMBincremental net monetary benefitsLMIClower middle-income countriesLRTIlower respiratory tract infectionsNHNorthern HemisphereNIAIDNational Institute of Allergy and Infectious DiseasesPPCPreferred product characteristicsRrecoveredRvRecovered-vaccinatedSSusceptibleSARIsevere acute respiratory illnessSHSouthern HemisphereSvSusceptible-vaccinatedURTIupper respiratory tract infectionsUSDUS DollarsVEVaccine efficacyWHOWorld Health OrganisationWTPWillingness-to-pay